氢化可的松用于CKD患者感染性休克
本研究基于TriNetX美国数据库的回顾性队列,纳入非透析CKD合并感染性休克患者,经倾向评分匹配后比较使用与未使用氢化可的松各13,141例。结果显示氢化可的松组90天全因死亡风险更高(HR 1.31,95%CI 1.25-1.36),MAKE、MACCE和机械通气风险也增加,但再感染风险降低。
要点
- CKD合并感染性休克患者使用氢化可的松与90天死亡风险增加相关(HR 1.31)。
- 氢化可的松组MAKE、MACCE及机械通气风险均升高。
- 氢化可的松组再感染风险降低(HR 0.88),高血糖和谵妄无差异。
核心结论
- 在CKD合并感染性休克患者中,使用氢化可的松与死亡、心肾及肺部不良结局风险增加相关,但再感染风险降低。
研究设计与样本
- 经1:1倾向评分匹配后,氢化可的松组和对照组各13,141例,平均年龄70±12岁,46%女性。
主要发现
- 氢化可的松组90天全因死亡4263例(32.4%),对照组3654例(27.8%),调整后HR 1.31(95%CI 1.25-1.36)。
- 氢化可的松组MAKE风险HR 1.08(95%CI 1.05-1.12),MACCE风险HR 1.19(95%CI 1.15-1.24),机械通气风险HR 1.34(95%CI 1.27-1.41)。
- 氢化可的松组再感染风险HR 0.88(95%CI 0.85-0.91),高血糖HR 1.04(95%CI 1.00-1.07)和谵妄HR 1.07(95%CI 1.00-1.14)无差异。
临床怎么用
- 在CKD合并感染性休克患者中,使用氢化可的松需权衡死亡和心肾风险增加与再感染风险降低的利弊。
局限性
- 回顾性观察性设计可能存在残余混杂,研究结果需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with chronic kidney disease (CKD) are at higher risk of septic shock and mortality than the general population. Although hydrocortisone is often used as an adjuvant therapy for septic shock in the general population to improve clinical outcomes, its effectiveness in patients with CKD remains understudied. METHODS: We identified a retrospective cohort of patients within TriNetX US collaborative database diagnosed with nondialysis CKD between November 1, 2010 and October 31, 2025 who also developed septic shock. Outcomes of interest within 90 days included all-cause mortality, major adverse kidney events (MAKE) without persistent kidney dysfunction, major adverse cardiovascular or cerebrovascular events (MACCE), mechanical ventilation, hyperglycemia, reinfections, and delirium. Survival analyses and multivariable Cox proportional hazard models were performed. RESULTS: One to 1, we propensity-score matched 13,141 CKD patients with sepsis treated with hydrocortisone with 13,141 CKD patients with sepsis not treated with hydrocortisone. Our cohort had a mean age of 70 ± 12 years and was 46% female, 21% African American, and 5% Hispanic. Most patients had hypertension (95%), were diabetic (63%), and had ischemic heart disease (68%). Mean serum creatinine concentration was 2.3 ± 2.7 mg/dl, mean lactate concentration was 3 mmol/l, and 25% of patients required mechanical ventilation. In this propensity-score matched analysis, more patients died in the group given hydrocortisone than in the group not given hydrocortisone (4263 [32.4%] vs. 3654 [27.8%]) with adjusted hazard ratio (HR) 1.31 (95% confidence interval [CI]: 1.25-1.36). Hydrocortisone group had higher risk of MAKE HR 1.08 (95% CI: 1.05-1.12), MACCE HR 1.19 (95% CI: 1.15-1.24), and mechanical ventilation HR 1.34 (95% CI: 1.27-1.41) but lower reinfections HR 0.88 (95% CI: 0.85-0.91) and no differences in hyperglycemia HR 1.04 (95% CI: 1.00-1.07) and delirium HR 1.07 (95% CI: 1.00-1.14). CONCLUSION: In this large, national, multicenter retrospective cohort of patients with CKD and septic shock, use of hydrocortisone was associated with increased risk of mortality, cardiorenal, and pulmonary outcomes, but reduced risk of reinfections. These findings warrant more research to rigorously evaluate the effects of hydrocortisone use in septic shock for this high-risk population.
引用
- Dhamelia P, Abeyagunawardene H, Kore RA, et al. Hydrocortisone Use for Septic Shock in Patients With CKD. Kidney Int Rep. 2026. PMID: 42500310. doi:10.1016/j.ekir.2026.106686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。